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Abstract

Objectives: To describe our statewide pharmacist-led, education campaign to increase
knowledge and awareness of pneumococcal immunization recommendations.
Setting: Immunization providers and residents in the State of Rhode Island.
Practice description: A clinical pathway (i.e., decision-support tool) was developed to educate
healthcare professionals about appropriate indications, administration schedules, and frequently
asked questions for the two different adult pneumococcal vaccines. Academic detailing and
distribution of the clinical pathway to healthcare professionals was conducted across Rhode
Island. Community outreach activities included radio ads, as well as distribution of patient
handouts and wallet cards at community events.
Practice innovation: To our knowledge, this was the first statewide pharmacist-driven academic
detailing and community outreach campaign to promote adult pneumococcal vaccination.
Evaluation: Academically-detailed immunization providers received a six-question survey.
Pneumococcal disease rate differences between the study periods were evaluated with Fisher’s
exact tests, while changes in vaccination were assessed with chi-square tests.
Results: From November 2013 through July 2015, our academic detailers visited and/or
distributed our vaccination pathway materials to over 400 practice sites across Rhode Island,
including 68% of community pharmacies and all adult acute care hospitals. Of the 413 surveys
completed, 92% of respondents agreed that their knowledge of the PCV13 and PPSV23 vaccines
had improved. Pneumococcal vaccination increased significantly (absolute difference 3.9%,
percent change in proportion 5.4%; p=0.01) and pneumococcal disease decreased significantly
between the pre-intervention and intervention periods (-2.74/10,000 discharges, 95% confidence
interval [CI] -5.15, -0.32; p=0.02). Invasive pneumococcal disease decreased by 21 cases per
1,000,000 population per year between the pre-intervention and post-intervention periods (95%
CI -42.25, 0.14; p=0.05).
6

Conclusion: Our statewide pharmacist-driven pneumococcal vaccination educational outreach
program resulted in favorable provider feedback relative to knowledge change and perceptions.
Vaccination increased while pneumococcal disease decreased during the study period.
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Key Points
Background
•

Pneumococcal vaccination remains well below the Healthy People 2020 goal of 90% in older
adults, both nationally and in Rhode Island.

•

Prior to the intervention, Rhode Island had a higher burden of invasive pneumococcal disease
than the rates observed regionally or nationally.

•

Pneumococcal vaccination recommendations have undergone several changes in recent
years, including expanded indications for vaccination.

Findings
•

Pharmacist-led academic detailing sessions improved self-reported immunization provider
knowledge of PCV13 and PPVSV23 vaccination recommendations, resulting in intentions to
apply this knowledge in clinical practice and expected changes in their vaccination practices.

•

Since implementing our academic detailing and community outreach intervention in Rhode
Island, (1) invasive pneumococcal disease decreased despite increases in New England
during the same time period, (2) pneumococcal vaccination increased significantly, and (3)
there were significantly fewer pneumococcal disease hospital discharges.

8

Introduction
More than half of pneumococcal disease in older adults occurs in non-vaccinated patients who
have an indication for pneumococcal vaccination.1,2 Moreover, an estimated 67 million at-risk
individuals in the United States (US) have not yet been vaccinated.1,2 This data is extremely
concerning because patients with Advisory Committee on Immunization Practices (ACIP)
indications for pneumococcal vaccination are twice as likely to die as those without indications if
they develop invasive pneumococcal disease.3 Despite this grave reality, and efforts to improve
national pneumococcal vaccination rates among populations that should be vaccinated,
vaccinations rates rarely reach 75%.4-6 Pneumococcal vaccination in adults aged 65 years and
older has remained relatively stable over the past several years, however, it is still well below the
Healthy People 2020 goal of 90%.4

A significant challenge with adult vaccinations, as opposed to childhood vaccinations, is
awareness of vaccination indications among immunization providers and patients.7-10 This is
particularly problematic in adult populations since vaccine status assessment by healthcare
providers is not routine, patients often receive care at multiple locations (indicating care may not
be coordinated), and patients may be unaware of their immunization status.7-10

Further,

pneumococcal vaccination recommendations have undergone several changes in recent years
and can be complex depending on the patient’s age, medical conditions, and previous
pneumococcal vaccination status.11-15

Objectives
We developed a statewide pharmacist-led, education campaign utilizing academic detailing and
patient outreach to improve adult pneumococcal rates by increasing knowledge and awareness
of pneumococcal immunization recommendations. To assess the effectiveness of our approach
for improving pneumococcal vaccination in Rhode Island through education, we evaluated a
9

range of outcomes, including changes in vaccination rates, invasive pneumococcal infections,
and pneumococcal pneumonia, as well as provider feedback on academic detailing.

Setting
Our education campaign targeted immunization providers and residents of Rhode Island.
Immunization providers were educated in the practice setting, as well as at conferences and
meetings. Patients were educated at community events and through radio announcements.

Practice description
Decision pathway and educational materials
The pharmacist-led academic detailing team developed a vaccination pathway (i.e., clinical
decision-support tool) designed to address the complex pneumococcal vaccine administration
schedules and corresponding indications, which served as a central component for immunization
provider education.

The pathway was developed based on the Advisory Committee on

Immunization Practices (ACIP) adult pneumococcal vaccination recommendations, the Center for
Disease Control and Prevention, and the Infectious Disease Society of America (IDSA), along
with information from the Immunization Action Coalition and prescribing information for both types
of adult pneumococcal vaccinations (PPSV23 and PCV13; see Supplementary File, also available
at http://web.uri.edu/antimicrobial-stewardship/infections-by-organism/).11-15 After initial pathway
development, local infectious disease specialists were asked to provide critical analysis and
feedback to help ensure the final pathway provided complete information in an easy-to-follow
format.

When necessary, the pathway was updated to reflect the most current guideline

recommendations. The vaccination pathway was reviewed and approved by the Rhode Island
Department of Health and copyrighted by the University of Rhode Island Office of Intellectual
Property and Economic Development.
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The four-page pathway document was laminated and held together by a corner ring for durability
and accessibility in the clinical setting. The pathway included the adult pneumococcal vaccination
recommendations and schedule for both PPSV23 and PCV13, medical conditions requiring
pneumococcal vaccination, facts about pneumococcal disease, frequently asked questions about
pneumococcal vaccination, package insert information on both types of pneumococcal
vaccinations, as well as contraindications, side effects, and precautions. Contact information for
the major insurance carriers in Rhode Island was also provided.

A patient vaccination wallet card and pneumococcal vaccination patient information handout were
also created. The wallet card included space to record vaccination status for multiple adult
immunizations and important medical information. A wallet card sleeve was incorporated to
protect the wallet card and included a reminder to “please carry this with you and show to your
healthcare professional”. The wallet card was approved by the Rhode Island Department of
Health and the Ocean State Adult Immunization Coalition. An educational patient handout was
developed and included information on the dangers of pneumococcal disease, who should be
vaccinated, and prompted patients to contact their immunization providers to get vaccinated. The
handout was developed using resources from the Immunization Action Coalition, the National
Foundation for Infectious Diseases, and scholarly articles. The wallet card, wallet card sleeve,
and patient handout were all printed in English and in the 5 most common foreign languages
spoken in Rhode Island since 5.7% of households in Rhode Island are linguistically isolated.

Academic detailing
Implementation, immunization providers
In an effort to introduce our vaccination pathway to immunization providers throughout the state,
our team (Authors JMD, KEW, KO, KLL, Group [JPB, MLC, BF, VL], Acknowledgements [TJK,
RM, NRD]) attended 22 events with pharmacist, physicians, and nurse attendees. Presentations
11

on our vaccination pathway were made to the Rhode Island Department of Health Flu Task Force,
Rhode Island Certified Diabetes Outpatient Educators, Ocean State Adult Immunization Coalition,
Wellness Company Nurses Protocol Meeting, Seminar by the Sea Northeast Regional Continuing
Education Conference for Pharmacists, Rhode Island Pharmacists Foundation, Coastal Medical
of Rhode Island, Rhode Island Department of Health Nurses Conference, and Economic Burden
of Vaccine Preventable Diseases in Rhode Island.

Additionally, we mailed copies of our

vaccination pathway to hospitals and clinics in both Rhode Island and surrounding states. Events
and mailings were either planned based on outreach efforts by the project team or by request of
the event host or facility.

All materials distributed during our statewide academic detailing and community outreach
campaign were made available for download from the URI Drug Information Services website
(http://web.uri.edu/pharmacy/drug-info/) to ensure continued access to the vaccination pathway
and patient handouts and to make the materials available to a wider audience. An email with the
link to the website was sent to approximately 50 immunization providers in the state.

Implementation, community pharmacies
A list of all CVS, Rite Aid, Target, and Walgreens pharmacies in Rhode Island was compiled. The
URI College of Pharmacy has full-time faculty, adjunct faculty, and preceptors with clinical practice
sites in community pharmacies across the state.

The College’s relationships with these

pharmacies enabled us to present our pneumococcal vaccination pathway and conduct academic
detailing at 68% (121/177) of Rhode Island pharmacies from November 2013 through July 2015.
The academic detailers included URI faculty, a community pharmacy resident, and a student
pharmacist. Various academic detailing methods were used to reach as many immunization
providers as possible in the state. A 1-to-1, face-to-face approach was utilized at all of the CVS,
Rite Aid, and Target pharmacy sites visited. Sessions lasted approximately 15 minutes, and each
12

participant was provided education on how to use the pneumococcal vaccination pathway,
vaccination indications, and the recommended schedule of vaccination. Academic detailing for
Walgreens pharmacies consisted of a 20-minute presentation at the Walgreens District meeting
of 70 pharmacy managers. Academic detailing sessions also occurred during two Rite Aid district
meetings (23 stores).

Patient outreach
To further improve communication and coordination between patients and their immunization
providers, a Public Service Announcement (PSA) was developed in collaboration with the Rhode
Island Department of Health and Ocean State Adult Immunization Coalition, which aired in English
and Spanish on Rhode Island radio stations: “Do you have diabetes or asthma? Do you smoke?
Are you over 65 years of age? If you answered yes to even one of these questions, you are at
increased risk for bacterial pneumonia. Bacterial pneumonia is an infection of the lungs. It’s a
dangerous disease that could send you to the hospital. In some cases, it can even be deadly.
The good news is that you can protect yourself. Ask your doctor or pharmacist about the vaccine
that protects against bacterial pneumonia. Vaccination - it’s your best defense. Sponsored by
the University of Rhode Island College of Pharmacy and the Rhode Island Department of Health”.
Our target audience for the PSA was adults 65 years and older, and based on demographics
provided by the advertising company, six radio stations were chosen. The PSA aired a total of
227 times in December 2014.

To reach patients of diverse backgrounds throughout Rhode Island, the study team and the URI
Pharmacy Outreach Program attended over 100 public health events over the intervention period.
Events included public health fairs, such as the Feed 1,000 Rhode Islanders event for two
consecutive years, brown bag events, support groups, and educational programs held at senior
centers, senior housing, and community centers. Wallet cards, patient handouts, and sticks of lip
13

balm promoting pneumococcal vaccination were distributed to attendees. At several events,
formal presentation about pneumococcal disease and pneumococcal vaccination were made to
attendees.

Practice innovation
To our knowledge, this is the first statewide pharmacist-driven academic detailing and community
outreach campaign to promote adult vaccination.

Academic detailing is “university or non-

commercial-based educational outreach which involves face-to-face education to prescribers by
trained healthcare professionals".16,17 The goal of academic detailing is to provide education
consistent with medical evidence and guidance documents.16,17

With the complexity of

recommendations for pneumococcal vaccination, development of an easy-to-understand pathway
and corresponding educational materials served as the backbone for our academic detailing
efforts. Prior to pathway development, implementation of the ACIP recommendations was difficult
due to a lack of public and provider knowledge, electronic medical record systems that did not
automatically recommend the correct vaccine, and perceived and actual financial/reimbursement
limitations, mainly from the primary payer for older adults, Medicare.

Evaluation
Immunization provider survey
After academic detailing sessions, each provider participant was requested to take an anonymous
6 question survey about the effectiveness of their detailing session (see Supplementary File).
Surveys were either submitted electronically via Survey Monkey on an iPad, or paper surveys
were collected in a sealed envelope, depending on immunization provider preference. Domains
of survey measurement included content understanding, educational material ease of use,
satisfaction with the academic detailing session, confidence in applying the new knowledge in
practice, and intention to utilize the pathway and change vaccination practices. Each question
14

followed a 5-point Likert scale, from strongly disagree = 1 to strongly agree = 5. We assessed
the percent agreeing with each question (5 = strongly agree, 4 = agree). Health profession and
setting were collected in the survey and question responses were compared between groups
using the chi-square or Fisher’s exact tests as appropriate.

Pneumococcal vaccination and infections
Vaccination
Pneumococcal vaccination was determined from the Behavioral Risk Factor Surveillance System
(BRFSS), a national, cross-sectional survey which collects information about health behaviors,
disease, and preventive services, such as vaccination.6,18 We evaluated the percentage of adult
respondents 65 years and older who have ever had a pneumonia vaccination in Rhode Island
and the US. Percent changes in the proportion of respondents answering “yes” to this question
over the study period were assessed, as were absolute differences. Rhode Island BRFSS count
data was obtained from the Rhode Island Department of Health, and US percentages were
obtained from the Centers for Disease Control and Prevention BRFSS website.

Invasive pneumococcal disease, case reports
The goal of vaccination is to prevent morbidity and mortality, particularly invasive disease. As
such, we assessed changes in invasive pneumococcal disease in Rhode Island.

Invasive

pneumococcal disease has been a reportable disease nationally since 2010.19 Invasive disease
is confirmed by isolation of pneumococcus from blood, cerebrospinal fluid, pericardial fluid, pleural
fluid, peritoneal fluid, joint fluid, or other normally sterile site. Due to seasonal variations in
pneumococcal disease, calendar years were used to define the study periods.

The pre-

intervention period was January 1 through December 31, 2013, the intervention period was
January 1, 2014 through December 31, 2015, and the post-intervention period was January 1
through December 31, 2016. Due to the use of calendar years, the intervention period included
15

a 5 month wash-out period without active academic detailing or community outreach activities
which concluded in July 2015. Changes were compared between the pre-intervention and
intervention periods, and pre-intervention and post-intervention periods. We collected the number
of cases of invasive disease from Notifiable Disease and Mortality Tables from Morbidity and
Mortality Weekly Reports.20 Notifiable disease reports collected by individual states and territories
are sent to the Centers for Disease Control and Prevention, which are then published as weekly
disease rates and compiled into annual reports.20 Final reports and provisional reports were used
to calculate cases per study period (final report for 2016 not expected until late 2017).20
Population estimates, provided as estimates as of July 1 each year, were obtained from the United
States Census Bureau.21

Pneumococcal disease, hospital discharge data
We assessed pneumococcal disease from hospital discharge data collected by the Rhode Island
Department of Health. Discharge data is captured from 5 teaching hospitals providing general
acute care, 6 other general acute-care hospitals, 2 psychiatric teaching hospitals, and 1
rehabilitation hospital. International Classification of Disease, 9th revision (ICD-9) diagnosis codes
were used to identify pneumococcal disease: pneumonia 481, bacteremia 038.2, and meningitis
320.1. Due to the switch from ICD-9 to ICD-10, hospital discharge data was only available through
September 2015.

Statistical analysis
Discharge rates per 10,000 discharges and per 10,000 bed days were calculated. Invasive
disease was calculated per 1,000,000 population. Using OpenEpi, changes in vaccination (for
Rhode Island), infection type, inpatient mortality, and pneumococcal disease rate differences
between the study periods were evaluated with chi-square, Fisher’s exact, or t-tests, as
appropriate.22
16

Ethics approval
This project was reviewed by the Institutional Review Board of the University of Rhode Island and
was determined to be exempt according to federal regulations 45 CFR 46.101(b)(2) and 45 CFR
46.101(b)(4).

Results
Academic detailing
Academic detailing was assessed with surveys of licensed immunization providers. Overall,
immunization providers found the academic detailing sessions to be effective with easy to
understand materials (Tables 1 and 2). Most immunization providers agreed or strongly agreed
(92%) that their knowledge of identifying which patient populations meet the recommendations
for PCV13 or PPVSV23 improved. Providers intended to apply the knowledge in their clinical
practice (83%), and expected their vaccination practices to change as a result of the academic
detailing and education materials (73%).

Almost 90% of immunization providers found the

educational materials easy to understand. As compared with agreement in the community setting
(Table 1), there was significantly (p<0.05) less agreement with the questions in both the hospital
setting (Q2-Q6) and the private practice setting (Q1, Q3-Q5). As compared with agreement
reported by pharmacists (Table 2), there was significantly (p<0.05) less agreement with all of the
questions as reported by nurses.

Of the 74 respondents who provided additional comments, 62% gave positive feedback regarding
the detailer and/or materials, such as “Great flow chart, easy to read, very informative” and
“[Academic detailer] did a great job explaining all the information! I feel that I am able to really put
this new information into good practice.”

Of those providing positive feedback, 78% were

pharmacists. A quarter of the respondents providing additional comments found the pathway
17

and/or detailing session to be confusing, complicated, or lacking information (18/73), such as
“Difficult to follow and had to flip back and forth” and “I would like a better description on the 2
indications for Prevnar”. Of those that found the material or session confusing, 72% were nurses.
Other respondents noted that they do not vaccinate (3%) or were already implementing the
pneumococcal vaccination recommendations (4%).

Pneumococcal vaccination and infections
Vaccination
In the US, the percentage of adults 65 years and older who had ever received pneumococcal
vaccination increased from 69.5% in 2013 to 72.5% in 2015 (absolute difference 3.0%, percent
change in proportion 4.3%). In Rhode Island, pneumococcal vaccination increased significantly
from 72.4% (95% confidence interval [CI] 69.7-75.1) in 2013 to 76.3% (95% CI 73.8-78.8) in 2015
(absolute difference 3.9%, percent change in proportion 5.4%%; p=0.01).

Pneumococcal disease
After our pharmacist-led academic detailing program, annual rates of pneumococcal disease
declined significantly by 2.8 per 10,000 discharges (Table 3; p=0.02). This resulted in 0.5 fewer
bed days of care per 10,000 bed days (p=0.04). Rates of pneumococcal disease were largely
driven by pneumococcal pneumonia over the entire study period (79.2%). Compared to the preintervention period, the proportion of pneumococcal disease discharges in Rhode Island with
pneumococcal pneumonia decreased significantly in the intervention period (86.0% vs 75.5%;
p=0.01), and the proportion with pneumococcal bacteremia increased (24.3% vs 33.6%; p=0.06).
Inpatient mortality was significantly lower in the intervention period compared to the preintervention period (8.8% vs 3.6%; p=0.03).
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Before our academic detailing program began, the annual rate of invasive pneumococcal disease
was higher in Rhode Island (72/1,000,000 persons) than in New England (47/1,000,000 persons)
or the United States (53/1,000,000 persons), as shown in Table 4. While the annual rate of
invasive pneumococcal disease increased significantly in New England over the study period
(74/1,000,000 persons; rate difference 26.35, 95% CI 20.73, 31.98; p<0.0001), it decreased in
both the United States (45/1,000,000 persons; rate difference -7.78, 95% CI -8.87, -6.70;
p<0.0001) and Rhode Island (51/1,000,000 persons; rate difference -21.06, 95% CI -42.25, 0.14;
p=0.05). Comparing rates in Rhode Island to those in the US overall, Rhode Island had more
cases of invasive disease per year in the pre-intervention period (rate difference 19.47, 95% CI
3.22, 35.71; p=0.006). In the post-intervention period, the Rhode Island rate was similar to that
of the US (rate difference 6.19, 95% CI -7.46, 19.84; p=0.34).

Discussion
Since the implementation of our statewide academic detailing and community outreach
intervention to increase pneumococcal vaccination among older adults, vaccination in the state
increased significantly, and we observed other signals which infer increased vaccination,
including a 5% decline in inpatient mortality among patient with pneumococcal disease.23-25
Additionally, we observed significant decreases in pneumococcal disease. Though the decline in
invasive pneumococcal disease was at the boundary of statistical significance (p=0.05), Rhode
Island went from having nearly 20 more cases of invasive disease per year than the overall rate
for the United States, to having a similar rate in the post-intervention period. Further, although
there was a significant increase in cases of invasive pneumococcal disease in New England, we
observed a decrease in Rhode Island.

According to a recent systematic review, most academic detailing interventions have generally
targeted one specific provider type (40.0% physician, 33.7% pharmacist, 27.4% nurse), fewer
19

studies have implemented a multifaceted approach targeting various providers (23.2%), and only
about one third included community outreach (31.1%),.26 Further, more than half of studies only
measured one outcome (56.6%), and a majority of those measured clinician behavior (91.5%).26
Our intervention was multifaceted both in the intervention and measurement of outcomes. Few
studies have evaluated the impact of academic detailing on adult vaccinations, and fewer
assessed the impact on actual vaccination or diseases rates.27,28 One randomized controlled
study to increase the use of preventive services found that academic detailing and peercomparison feedback to physicians was no more effective in increasing influenza and
pneumococcal vaccination than educational reminders.29 However, academic detailing has been
effective for other medication management initiatives.30

Our statewide academic detailing efforts, along with the supporting pathway and educational
materials, impacted immunization providers’ perception of knowledge about pneumococcal
vaccination. Our survey results demonstrated that the academic detailing efforts increased
immunization providers’ perceived ability to identify patients eligible for pneumococcal vaccination
and many providers indicated that the new knowledge would be incorporated into their clinical
practice.

Provider survey results suggests the education through academic detailing with

supporting materials was effective for immunization providers in community settings but that
improvements could be made in regards to hospital and nurse education.

Pharmacists consistently noted the pneumococcal pathway materials assisted them and clarified
questions they had regarding recommendations for which patient populations should receive the
PPSV23 and PCV13 and the administration schedules. Individual 1-to-1 approaches were mainly
implemented to reach as many pharmacists as possible in their practice settings. The academic
detailers remarked on the difficulties in providing consistent academic detailing at community
pharmacies. Academic detailing in this setting is often challenging because of constraints on the
20

pharmacists’ time to step away from the workflow and this is dependent on prescription volume
as well as additional professional staffing at the pharmacy. A large group meeting of pharmacy
managers proved to be an efficient forum, allowing pharmacists the time to adequately review the
materials and pose questions of the detailer.

Limitations
First, national vaccination recommendations were updated over the study period and meant
outdated materials were in circulation. When this occurred, academic detailing was repeated in
community pharmacies, adding considerable time to the project and effort from the academic
detailers. The vaccination pathway did include the URI Drug Information Services website so that
immunization providers could access and download the most recent version of the pathway.
Second, to account for seasonal changes in pneumococcal disease, the study periods were
divided by calendar year, so the intervention period included a 5 month wash-out period without
active academic detailing or community outreach activities. Though academic detailing began in
November 2013, few sessions were conducted due to the holidays. As immediate effects on
statewide pneumococcal disease rates from these sessions were not expected, categorization by
calendar year was considered appropriate. Additionally, due to the switch from International
Classification of Diseases 9th Edition to 10th Edition in October 2015, the codes for pneumococcal
disease changed, and pneumococcal hospital discharges from the last quarter of 2015 onward
were not included as rate differences may have been artefactual. Therefore, the intervention
period for pneumococcal hospital discharges ended in September 2015.

Third, though

community pharmacies received two academic detailing sessions, different pharmacists may
have participated in the detailing sessions, and as such, we were not able to follow-up with
immunization providers to determine use of the academic detailing material in the practice or
whether the pathways changed their immunization practices. Fourth, we could not calculate a
response rate for the academic detailing survey. These results may be limited by response bias,
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since the exact number of attendees was not known for some academic detailing sessions, and
some pharmacists may have received academic detailing on multiple occasions.

Fifth, we

attempted to collect vaccination data from several sources, other than BRFSS, however, we were
not able to obtain these data. Lastly, we were not able to control for other factors that may have
influenced vaccination practices over time, including vaccine advertisements or internal
immunization provider policies to increase pneumococcal vaccination.

Conclusions
Our statewide pharmacist-driven campaign to increase adult pneumococcal vaccination through
academic detailing to immunization providers and community outreach efforts resulted in
increased self-reported provider knowledge regarding the pneumococcal vaccine. During the
study period, we observed increases in vaccination and decreases in pneumococcal disease in
Rhode Island.
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Table 1. Immunization provider survey of academic detailing, percent agreeing or strongly
agreeing, by setting
Question

Community

Ambulatory

Free clinic

care

N=4

Hospital

Private

Other

practice
N = 55

N = 19

N = 64

100.0%

89.1%

78.9%*

82.8%*

100.0%

75.0%

76.4%*

89.5%

73.4%*

96.8%

87.5%

100.0%

85.5%*

84.2%*

79.7%*

94.7%

87.5%

100.0%

74.5%*

73.7%*

62.5%*

93.9%

75.0%*

75.0%

67.3%*

73.7%*

59.4%*

82.2%

58.3%*

100.0%

60.0%*

68.4%

53.1%*

N = 247

N = 24

95.5%

91.7%

94.3%

Q1. My knowledge of
identifying which patient
population requires
PCV13 or PPVSV23 has
improved
Q2. The educational
material is easy to
understand
Q3. This academic
detailing session was
effective
Q4. As a result of this
education, I am confident
that I can apply this
knowledge in clinical
practice
Q5. As a result of this
education, I intend to
apply the vaccination
pathway in my practice
Q6. As a result of this
education, I expect my

vaccination practices to
change

* Significant (p<0.05) differences as compared with community setting.

Table 2. Immunization provider survey of academic detailing, percent agreeing or strongly
agreeing, by provider
Pharmacist

Nurse

N = 278

N = 95

Question

Nurse

Physician

Other

N=7

N = 29

Practitioner
N=4

Q1. My knowledge of
identifying which patient
population requires

96.0%

81.1%*

100.0%

71.4%*

89.7%

96.8%

61.1%*

100.0%

100.0%

96.6%

96.8%

72.6%*

100.0%

100.0%

100.0%

95.3%

65.3%*

100.0%

100.0%

55.2%*

91.0%

73.7%*

100.0%

85.7%

31.0%*

80.2%

64.2%*

100.0%

100.0%

24.1%*

PCV13 or PPVSV23 has
improved
Q2. The educational
material is easy to
understand
Q3. This academic
detailing session was
effective
Q4. As a result of this
education, I am confident
that I can apply this
knowledge in clinical
practice
Q5. As a result of this
education, I intend to
apply the vaccination
pathway in my practice
Q6. As a result of this
education, I expect my

vaccination practices to
change

* Significant (p<0.05) differences as compared with pharmacists.

Table 3. Change in annual rates of pneumococcal disease hospital discharges, Rhode Island
Pre-

Intervention

intervention

(Jan 1, 2014

Rate

(Jan 1, 2013 –

– Sep 30,

difference

Dec 31, 2013)

2015)

12.8

10.0

-2.74a

-5.15, -0.32

2.5

2.0

-0.50a

-0.98, -0.01

95%
Confidence
Interval

Rhode Island,
pneumococcal disease per
10,000 discharges
Rhode Island,
pneumococcal disease per
10,000 bed days
Source: hospital discharge data.
a Comparison

of pre-intervention and intervention periods significantly different (p<0.05).

Table 4. Change in annual rates of invasive pneumococcal disease
PostPre-

Intervention

intervention

(Jan 1, 2014

(Jan 1, 2013 –

– Dec 31,

Dec 31, 2013)

2015)

95%

intervention
Pre-post rate

Confidence

(Jan 1, 2016
difference

Interval

– Dec 31,
2016)
Rhode Island, invasive
pneumococcal disease per

72

64

51a

-21.06a

-42.25, 0.14

47

76b

74c

26.35c

20.73, 31.98

53

49b

45c

-7.78c

-8.87, -6.70

1,000,000 population
New England, invasive
pneumococcal disease per
1,000,000 population
United States, invasive
pneumococcal disease per
1,000,000 population
Source: Morbidity and Mortality Weekly Report data.
a Comparison
b

of pre-intervention and post-intervention periods, p=0.05.

Comparison of pre-intervention and intervention periods significantly different (p<0.05).

c Comparison

of pre-intervention and post-intervention periods significantly different (p<0.05).

Pneumococcal Vaccination Outreach
Educational Academic Detailing
Which choice best describes your health profession?
Physician
Nurse
Physician
Assistant
Practitioner

Nurse

Which choice best describes your primary workplace setting?
Ambulatory
Government
Community
Free clinic
care
hospital

Pharmacist

Hospital

Private
practice

Other

Other

Please indicate your degree of agreement with each statement.
Strongly
Agree

Agree

Neutral

Disagree

Strongly
Disagree

1. My knowledge of identifying which patient
population requires Prevnar 13® (pneumococcal
conjugate vaccine; PCV13) or Pneumovax® (23valent polysaccharide vaccine; PPVSV23) has
improved.
2. The educational material is easy to understand.
3. This academic detailing session was effective.
4. As a result of this education, I am confident that I
can apply this knowledge in clinical practice.
5. As a result of this education, I intend to apply the
vaccination pathway in my practice.
6. As a result of this education, I expect my
vaccination practices to change.
Comments for specific questions.

Please use the space below to add overall comments about the academic detailing or educational materials.

Adults ≥19 Years1-4

COLLEGE OF
PHARMACY

(Including updated recommendations for the use of PCV13 in Adults)

DRUG INFORMATION
SERVICES
401-874-9188

T

M

H

EA

LT H

RH

D

D E PAR

Pneumococcal Vaccination
Recommendations

E ISLA

N

OD

E N T OF

Healthy Adults ≥ 65
Pneumococcal Vaccination
Naive or Unknown History

Previously vaccinated with
PPSV23 at age ≥65

Previously vaccinated with
PPSV23 before age 65
≥ 1 year after PPSV23

GIVE: PCV13

≥ 1 year after PPSV23

Wait ≥ 1 year*

GIVE: PPSV23†

GIVE: PCV13 if not previously given
Wait ≥ 1 year*
(and ≥ 5 years after PPSV23)
GIVE: PPSV23†

GIVE: PCV13 if not previously given

ADULTS ≥ 19 with UNDERLYING MEDICAL CONDITIONS (see chart on back)
OR who SMOKE or live in a NURSING HOME
Pneumococcal Vaccination
Naive or Unknown History

Previously vaccinated with one
dose PPSV23

GIVE: PPSV23

At Age ≥65

GIVE: PCV13 ≥ 1 year after PPSV23
THEN: PPSV23† ≥ 1 year* after
PCV13 and ≥ 5 years after PPSV23

At Age ≥65

GIVE: PCV13 ≥ 1year after PPSV23
THEN: PPSV23† ≥ 1 year* after
PCV13 and ≥ 5 years after PPSV23

Vaccination is NOT
indicated for healthy persons
19 - 64 years of age
While PCV13 is FDA-approved for
persons > 50 years, the Advisory
Committee on Immune Practices
does not provide guidance for use
in this population.

ADULTS ≥ 19 with IMMUNE COMPROMISING CONDITIONS (see chart on back), OR ASPLENIA
(including sickle cell anemia), CEREBROSPINAL FLUID LEAK, or COCHLEAR IMPLANT
Pneumococcal Vaccination
Naive or Unknown History

Previously vaccinated with one
dose PPSV23

GIVE: PCV13

≥ 1 year after PPSV23

≥8 weeks* later

If < 65

GIVE: PCV13 if not previously given

If ≥65

If < 65 and
PPSV23
GIVE: second
PPSV23 §

PPSV23

GIVE: PCV13

if not previously given

PPSV23
GIVE: second
PPSV23 §

≥ 5 years after

≥ 5 years after

If ≥65

≥ 5 years after

If < 65 and

At Age ≥65

≥ 1 year after PPSV23

≥8 weeks* later

GIVE: PPSV23

GIVE: PPSV23†

Previously vaccinated with
two doses of PPSV23

GIVE: PPSV23†

At Age ≥65

GIVE:

PPSV23†

≥ 5 years after

PPSV23

GIVE: PPSV23†
≥5 years after
PPSV23

At Age ≥ 65

GIVE: PPSV23† ≥ 8 weeks* after
PCV13 and ≥ 5 years after PPSV23

*

Minimum interval
between
sequential administration of PCV13 and PPSV23 is 8 weeks in immunocompromised patients.
GIVE:
PPSV23
For Medicare reimbursement interval must be 11 full months. Please refer to page 4.
† The ACIP (Advisory Committee on Immunization Practices) recommends only 1 dose of PPSV23 at age ≥65. Revaccination is not necessary.
§ A second PPSV23 for patients with cerebrospinal fluid leak, or cochlear implant is not required.
PPSV23=23-Valent Pneumococcal Polysaccharide Vaccine (Pneumovax®23)
PCV13=13-Valent Pneumococcal Conjugate Vaccine (Prevnar 13®)
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Pneumococcal Vaccination Information Sheet
PCV13 (Prevnar 13®) and PPSV23 (Pneumovax® 23)

COLLEGE OF PHARMACY

Facts About Pneumococcal Disease:
•

Streptococcus pneumoniae bacteria (i.e., pneumococci) are usually found in the upper respiratory tract of
most people.

•

Pneumococcal disease most commonly presents as a serious infection in the lungs (pneumonia), blood
(bacteremia), or brain (meningitis). The annual U.S. case estimate for invasive pneumococcal disease
(bacteremia and/or meningitis) is 40,000 and 4,250 deaths.

•

Pneumococcal disease most often occurs in older people as well as in people with a predisposing condition
(e.g., immunosuppression, pulmonary disease, heart disease, diabetes). The disease rates for adults in
these groups can be more than 20 times those for adults without high-risk medical conditions.

•

PPSV23 is 60–70% effective in preventing serious pneumococcal disease; it does not provide substantial
protection against all types of pneumonia (viral and bacterial). It is not a “pneumonia” vaccine.

Frequently Asked Questions:
Question: Can I get the influenza and pneumococcal vaccines at the same time?
Yes. These vaccines can be given at the same time. If giving two IM vaccinations, separate by one inch in the
body muscle to reduce likelihood of local reactions overlapping.
Question: If patients who are in a recommended risk group for PPSV23 or PCV13 aren’t sure if they
have previously received these vaccines, should healthcare providers vaccinate them?
Yes. If patients do not have a documented vaccination history for these two vaccines and their records are not
readily obtainable, you should administer the recommended doses. Extra doses will not cause harm to the
patient.
Question: Is an egg allergy a contraindication for PCV13 or PPSV23?
No. Both vaccinations are safe for persons with egg allergies.
Question: If my state has a registry, do I still need to give patients vaccine record cards?
Yes. Patient-held cards are an extremely important part of a person’s medical history. The person may move
to an area without a registry, and a personal record may be the only vaccination record available. In addition,
even within a state, all healthcare providers may not participate in the registry, and the personal record card
would be needed.
Question: My patient has had laboratory-confirmed pneumococcal pneumonia. Does he/she still need
to be vaccinated with PPSV23?
Yes. There are more than 90 known serotypes of pneumococcus (23 serotypes are in the current vaccine).
Infection with one serotype does not necessarily produce immunity to other serotypes. As a result, if the
person is a candidate for vaccination, he/she should receive it even after one or more episodes of invasive
pneumococcal disease.
Question: Why is pneumococcal vaccination recommended for smokers and asthmatics?
In 2008, the Advisory Committee on Immunization Practices (ACIP) reviewed new information that suggests
that asthma is an independent risk factor for pneumococcal disease among adults. ACIP also reviewed new
information that demonstrates an increased risk of pneumococcal disease among smokers. Consequently,
ACIP recommends to include both asthma and cigarette smoking as risk factors for pneumococcal disease
among adults age 19 through 64 years and as indications for PPSV23.
Acquired from www.immunize.org on September 4, 2013. We thank the Immunization Action Coalition.
MMWR Morb Mortal Wkly Rep 2012; 61(40):816-819.

Pneumococcal Vaccination Information Sheet
PCV13 (Prevnar 13®) and PPSV23 (Pneumovax® 23)
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PPSV23 (Pneumovax®23)

PCV13 (Prevnar13®)

Manufacturer:

Manufacturer:

Merck
www.merckvaccines.com/Products/Pneumovax/Pages/home

How Supplied:

Pfizer
http://www.pfizerpro.com/hcp/prevnar13

How Supplied:

0.5mL Single Dose Vial
Multi-Dose (5 dose Vial)

Prefilled Syringe
(10 per Package)

Storage and Handling:

Storage and Handling:

Refrigerate on Arrival
Store at 2◦C to 8◦C
DO NOT FREEZE
Discard after the expiration date

Refrigerate on Arrival
Store at 2◦C to 8◦C
DO NOT FREEZE
Discard after the expiration date

Special instructions:

Special instructions:

None

Shake well to obtain a homogeneous white suspension

Route of Administration:

Route of Administration:

0.5mL IM or SQ

0.5mL IM ONLY

Insurance Carrier Information:
Medicare www.medicarenhic.com 1-866-801-5304*
BCBS of RI www.bcbsri.com/providers 401-274-4848 1-800-230-9050
UnitedHealthCare www.unitedhealthcareonline.com 1-877-842-3210
RI Department of Health State Supplied Vaccination Program www.health.ri.gov/resources/immunization/

Contraindications and Precautions:
• Do not give PPSV23 or PCV13 to patients who have a history of a serious reaction (e.g., anaphylaxis) after
a previous dose of PCV13, PPSV23, or one of their components.
• Do not give PPSV23 and PCV13 simultaneously. For vaccine naive patients, give PCV13 first, followed by a
dose of PPSV23 ≥ 1 year† (unless patient in a population specified by ACIP to require shorter interval, see
page 1). For patients who have already received PPSV23, give PCV13 12 months after the most recent
dose of PPSV23.
• Vaccine Co-administration: (1) all vaccines used for routine vaccination in the United States can be given on
the same day; (2) an inactivated vaccine can be administered either on the same day as or at any time
before or after another inactivated or a live vaccine; and (3) any 2 LIVE vaccines that are not given on the
same day must be spaced at least 4 weeks apart. Zoster vaccine is a live, attenuated vaccine; injectable
influenza vaccine and pneumococcal polysaccharide vaccine are inactivated vaccines. So these 3 vaccines
can be given on the same day or at any time before or after each other. They should be given as separate
injections, not combined in the same syringe.

Side Effects:
• Most common side effects from either PPSV23 or PCV13 are soreness and redness at the injection site,
lasting 1-2 days.
Drug Information Services 401-874-9188

Monday-Friday 8:30 am - 4:00 pm EST

initial pneumococcal vaccine may be administered to all Medicare beneficiaries who have never received a pneumococcal vaccine under Medicare Part B. A different, second
* An
pneumococcal vaccine may be administered 1 year after the first vaccine was administered (i.e., 11 full months have passed following the month in which the last pneumococcal vaccine
was administered). Please note that the “interval” between the two different pneumococcal vaccines must be at least 11 full months or greater for Medicare reimbursement, not the
shorter “interval” recommended for specific populations identified by ACIP.
Acquired from www.immunize.org on September 4, 2013. We thank the Immunization Action Coalition.

† Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee in Immunization Practice (ACIP)
MMWR Morb Mortal Wkly Rep. 2015; 64(34): 944-947.

